Region
Featured experience
Guotai Junan merger with Haitong and concurrent placement of shares
We advised Guotai Junan Securities on the transaction, creating the largest securities company in China
Chagee $411.2 million IPO
We advised Chagee on its IPO and Nasdaq listing
Tencent €1.16 billion investment in new Ubisoft subsidiary
We are advising Tencent on the transaction
iQIYI $350 million convertible notes offering and concurrent private repurchases
We advised iQIYI on the transactions
China Resources Beer RMB12.3 billion acquisition of Jinsha Winery
We advised China Resources Beer on the acquisition of a controlling interest in Jinsha Winery
Bilibili convertible notes exchange and concurrent follow-on equity offering
The transaction involved a convertible notes exchange and a concurrent follow-on offering of ADSs
Sirio Pharma acquisition of a majority stake of Best Formulations
We advised Sirio Pharma on the acquisition
Kingsoft Cloud dual primary listing on the Hong Kong Stock Exchange
We advised Kingsoft Cloud on its dual primary listing by way of introduction on the HKEX
Xiamen ITG $200 million bonds offering
The 6.5% guaranteed bonds are due 2023
Atour Lifestyle Holdings $52 million IPO
We advised Atour on its IPO and Nasdaq listing
Complete victory for X Financial in IPO-related litigation
We secured the dismissal of two securities class actions related to the company’s 2018 IPO
DFZQ $300 million bonds offering
The investment-grade bonds are due 2025
Total victory in securities class actions related to COVID-19 pandemic
We secured dismissals of state and federal securities cases on behalf of Chinese audio platform Lizhi
InnoCare Pharma RMB2.9 billion Shanghai IPO
This is the largest A-share listing by an overseas-listed biotechnology company in 2022 so far